Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) FCF Margin (2020 - 2025)

Cytek Biosciences' FCF Margin history spans 6 years, with the latest figure at 7.68% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1101.0% year-over-year to 7.68%; the TTM value through Dec 2025 reached 4.35%, down 1693.0%, while the annual FY2025 figure was 4.35%, 1693.0% down from the prior year.
  • FCF Margin reached 7.68% in Q4 2025 per CTKB's latest filing, down from 2.98% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 25.72% in Q3 2024 to a low of 25.52% in Q2 2022.
  • Average FCF Margin over 5 years is 1.46%, with a median of 3.52% recorded in 2025.
  • Peak YoY movement for FCF Margin: surged 3732bps in 2024, then tumbled -2870bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 6.63% in 2021, then soared by 39bps to 4.07% in 2022, then soared by 438bps to 13.76% in 2023, then crashed by -76bps to 3.34% in 2024, then tumbled by -330bps to 7.68% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's FCF Margin are 7.68% (Q4 2025), 2.98% (Q3 2025), and 4.57% (Q2 2025).